Libio Technology
↗Suzhou, China
Libio Technology is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative RNA interference (RNAi) therapies. The company focuses on addressing unmet medical needs in chronic diseases, particularly in the cardiovascular, metabolic, and renal therapeutic areas. Libio utilizes proprietary delivery platforms, including GalNAc-based liver targeting and extra-hepatic delivery technologies, to create long-acting siRNA medicines.
Founded in 2021 by veterans of the global pharmaceutical industry, the company has rapidly advanced its internal pipeline. Its lead candidates target high-prevalence conditions such as hypercholesterolemia and hypertension, aiming to provide patients with infrequent (bi-annual) dosing options that improve compliance and outcomes compared to traditional small molecule or antibody therapies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:Pre-revenue
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$50M
Investors:Legend Capital, GL Capital, BioBAY (Suzhou Industrial Park), Sherpa Healthcare Partners
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1 (LB-001)
Modalities:siRNA, RNAi, GalNAc-conjugates
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Collaborations with Suzhou BioBAY for R&D infrastructure, Academic partnerships with Soochow University
COMPETITION
Position:Emerging
Competitors:Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, SanegeneBio, Ribolia (Ribo Life Science), Silence Therapeutics
LEADERSHIP
Key Executives:
Dr. Chen Li - CEO
Scientific Founders:Dr. Chen Li
Board Members:Representatives from Legend Capital and GL Capital
LINKS
Website:libiotek.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Libio Technology. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.